The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. - Wikidata - awgldk - TriplyDB

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.

http://www.wikidata.org/entity/Q38202816

about

Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial.An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy.UGT1A1 polymorphisms in cancer: impact on irinotecan treatment.Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice.Current and future biomarkers in the treatment of colorectal cancer.Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.Advances and challenges in hereditary cancer pharmacogenetics.A Critical Evaluation of Pharmacogenetic Information in Package Inserts for Selected Drugs Marketed in India and Its Comparison With US FDA-Approved Package Inserts.Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.Germline genetic variants with implications for disease risk and therapeutic outcomes.Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.

P2860

Q28068930-DCA353BE-0E7C-4252-8EA4-AB366D5CFB74 Q33427471-756FAB5D-3C46-4E5E-8184-F2EF637D8894 Q35603648-09E69F87-669D-4206-A091-2493151D3679 Q36815039-11EB9ACA-FF62-4877-97D3-8FCA8CDFED1A Q37682812-BD144A56-CDF7-4593-8C51-034ACBDB8BC8 Q37726433-2A772689-1515-4191-AE21-FAFA2A4C7775 Q38393997-16057F7D-89ED-4DF8-A876-CE8477CA479E Q38787244-D0107B22-321A-46DE-A3B8-4CDFAFEA7B39 Q38922471-1C2DAD0A-C1CA-4CDD-80A9-049AF4C98B09 Q38948499-33EC1380-CB0D-4025-88B0-0737E508A546 Q40000464-43E3984B-DCBD-46AB-8938-BFB702F31942 Q40725730-D130BF3D-9AEB-42EC-9D33-64300E51C0F9 Q48100807-F4D11446-E952-4073-855F-65DFE81B53E4 Q52362144-C3B39F98-F316-427C-8F42-0D62E61F4E82 Q55497899-5E162B6E-576F-4197-A2B9-B3BB594791CC

P2860

The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis.

http://www.wikidata.org/entity/Q38202816

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The effect of the UGT1A1*28 al ...... a collaborative meta-analysis.

@en

type

label

The effect of the UGT1A1*28 al ...... a collaborative meta-analysis.

@en

prefLabel

The effect of the UGT1A1*28 al ...... a collaborative meta-analysis.

@en

P1433

Q38202816-E5D82943-4925-46D1-A1E4-AE1EDD8C778B

P1476

Q38202816-6103758B-40BA-447F-9B69-7EF4F702D1A0

P2093

Q38202816-3811873A-C271-4826-8BE9-0619646D7A46

Q38202816-47DC295F-B0C3-4E94-B505-EBB25693DF13

Q38202816-49CFD809-40D6-4753-ADCC-2535AF634481

Q38202816-6ED507B2-2AF1-48D0-A183-A4203825D860

Q38202816-A282304B-51D8-40DC-A5CE-8D5854F26C2B

Q38202816-B4140411-6ACA-4A33-929D-FB149CE7E275

Q38202816-E09D741E-052C-46B9-BA76-D27E51A589AD

P2860

Q38202816-136D485A-965C-40E2-94FA-A63BA72DF54D

Q38202816-1AD306B2-37FA-4B7B-99E2-63BA7E37119B

Q38202816-1AFB658F-DDB4-467D-8A16-68245914B97E

Q38202816-20C43BBD-B811-458C-9C4C-14162BD429FE

Q38202816-25CACCB0-33D8-466D-A7E2-6DBBD35EBD92

Q38202816-2BE03EB9-D2D2-42B7-928F-4B650F03EF01

Q38202816-2D611AB0-50CE-4C91-A51E-5D2D50505660

Q38202816-31260134-1A07-47AF-89ED-D75F21C9F78D

Q38202816-3669A64D-F0A7-4D87-A346-68E3A342B217

Q38202816-37E00238-2035-4D64-8311-F0ED9A14FA2B

P2888

Q38202816-F86D7D8B-1663-4D45-8A5B-6B6E89B95B78

P304

Q38202816-EE675FE0-0879-4FF5-A86B-975042450B01

P31

Q38202816-1b3db630-200f-4634-894a-42f940554671

Q38202816-22998219-6962-449F-9FD1-7C5CF3AD1A95

P356

Q38202816-0F4AC024-37EA-4E6F-A599-B5A5A5C996F6

P433

Q38202816-A079B1F7-90E1-4B2E-8D70-FA3BBA7E41C7

P478

Q38202816-8D4CC23E-D68D-48F1-B8D9-9BA9970EE987

P50

Q38202816-171C03DA-3019-4A85-9126-2862E6DB59A7

Q38202816-431051E2-54F5-40EC-B1D1-35D1880D72CD

Q38202816-6FA39A81-E97C-49FA-B351-E60FA62BDF67

Q38202816-81CEED2D-F18C-4061-B74B-11C1D588B9EA

Q38202816-898A6CEF-2C9D-418E-A557-4C11B1B87B38

Q38202816-941AB54B-ADC4-44B3-8837-A137D72066DF

Q38202816-B67E4D5B-3348-41EE-BD01-EE13C9C3D627

Q38202816-BD4AAF20-632A-486F-9902-F21282884E51

Q38202816-E57FFB2A-6722-426B-BE63-746F91AE8746

P577

Q38202816-F0F8CD84-B7C4-42D2-BF2A-6A6AEA5EFC78

P5875

Q38202816-B1E22D58-9CD9-45DE-BFBF-C6B85B6D72C0

P6179

Q38202816-BDFCCC38-FCBD-4209-9E4F-B67F191E6CED

P698

Q38202816-CD60E954-9814-4CD2-8F2E-D9F8E47FE784

P921

Q38202816-223D336B-75AF-465E-8E30-EDA220E8846C

Q38202816-BEBD224F-547C-4E4F-9FBA-517930FB32F6

P356

P1433

The Pharmacogenomics Journal

P1476

The effect of the UGT1A1*28 al ...... a collaborative meta-analysis.

@en

P2093

B Glimelius

http://www.w3.org/2001/XMLSchema#string

C J A Punt

http://www.w3.org/2001/XMLSchema#string

D M Kweekel

http://www.w3.org/2001/XMLSchema#string

D Páez

http://www.w3.org/2001/XMLSchema#string

M M Dias

http://www.w3.org/2001/XMLSchema#string

M W Redman

http://www.w3.org/2001/XMLSchema#string

P N Lara

http://www.w3.org/2001/XMLSchema#string

P2860

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

The Millennium Development Goals fail poor children: the case for equity-adjusted measures.

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement.

Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer.

Strengthening the reporting of Genetic RIsk Prediction Studies: the GRIPS Statement.

P2888

P304

424-431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/TPJ.2014.16

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Pierre Laurent-Puig

Michael J. Sorich

Ross A. McKinnon

Eva Martínez-Balibrea

Jean-Pierre Pignon

Christos S Karapetis

P577

2014-04-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261442708

http://www.w3.org/2001/XMLSchema#string

P6179

1017195614

http://www.w3.org/2001/XMLSchema#string

P698

24709690

http://www.w3.org/2001/XMLSchema#string

P921